L-carnitine is not just any ordinary component
Taking these supplements may lead to elevated thyroid hormone levels in the blood and cause symptoms of hyperthyroidism, which can lead to dangerous complications (12Trusted Source, 13Trusted Source, 14Trusted Source)
The risk was driven by the synthetic progestin What Modern Research Shows The French E3N cohort study (80,000+ women) found no increased breast cancer risk with bioidentical estradiol plus micronized progesterone for up to 5 years The "timing hypothesis" shows women starting HRT within 10 years of menopause receive cardiovascular benefit rather than harm The Danish Osteoporosis Prevention Study showed reduced heart failure, MI, and mortality over 16 years of follow-up Major medical organizations NAMS, Endocrine Society, and IMS now endorse HRT for symptomatic women within the appropriate window Risks and Contraindications Hormone therapy is not risk-free, and we believe in complete transparency
El uso de frmacos anlogos del GLP-1 est asociado con beneficios pero tambin riesgos para la salud El uso de agonistas del receptor del pptido similar al glucagn tipo 1 (GLP-1RAs, por sus siglas en ingls), utilizados para tratar la diabetes y la obesidad, podra estar asociado con un amplio espectro de efectos sobre la salud, tanto positivos como un menor riesgo de trastornos cardiometablicos como negativos un mayor riesgo de afecciones gastrointestinales o hipertensin
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
Renal outcomes in the EXenatide study of cardiovascular event lowering (EXSCEL)
